SecBot SecBot
SECBOTREPLAY Home › Report › UTHR

UTHR · United Therapeutics CEO Martine Rothblatt and EVP Paul Mahon…

UNITED THERAPEUTICS Corp · CLUSTER filed Aug 6, 2026 at 16:35 ET

At the news

MIXEDIMPACT 6/10

CLUSTER filed Aug 6, 2026 at 16:35 ET

United Therapeutics CEO Martine Rothblatt and EVP Paul Mahon collectively sold ~$490K in open-market shares within two days of the company's Q2 2026 earnings release, which showed a 2% YoY revenue miss ($783.3M vs. $804.6M consensus) but an EPS beat ($7.27 vs. $6.86). The sales follow option exercises and represent a small fraction of market cap, but the timing, right after a mixed earnings report with declining Tyvaso sales, raises watchfulness.

  • CEO Rothblatt sold 4,895 open-market shares on Aug 5, 2026, for ~$2.5M (including sales after option exercises).
  • EVP Mahon sold 8,300 open-market shares on Aug 6, 2026, for ~$4.3M (including sales after option exercises).
  • Total open-market sales in cluster: ~$6.8M, representing 0.03% of $22.6B market cap, trivial proportionally.
  • Q2 2026 revenue of $783.3M missed consensus by ~2.7% (down 2% YoY); EPS of $7.27 beat by 5.9%.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access